Kaleido Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kaleido Biosciences Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11047
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kaleido Biosciences Inc (Kaleido Biosciences) is a developer of human microbiomes for the treatment of infectious, rare genetic, inflammatory, oncology and metabolic diseases. The company’s human microbiome is a metabolic engine which is developed from healthy and diseased humans using various biotechnology techniques. It uses synthetic chemistry to design novel compounds with unique capability to improve specific outputs of the microbiome. Kaleido Biosciences’ novel chemistries are screened in its ex vivo microbiome platform that allows intact human microbiomes to be assayed in a high-throughput laboratory environment. The company discovers new chemistries to modulate the entire metabolic profile of the microbiome. Kaleido Biosciences is headquartered in Bedford, Massachusetts, the US.

Kaleido Biosciences Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Kaleido Biosciences Raises USD101 Million in Series C Venture Financing 10
Kaleido Biosciences Raises Additional Funds through Venture Financing 12
Partnerships 13
Kaleido Biosciences Enters into Agreement with CoreBiome 13
Kaleido Biosciences Inc – Key Competitors 14
Kaleido Biosciences Inc – Key Employees 15
Kaleido Biosciences Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Corporate Communications 17
Aug 21, 2018: Kaleido Biosciences names Alison Lawton as chief executive officer 17
Apr 23, 2018: Kaleido Biosciences Names Joshua Brumm As Chief Financial Officer 19
Mar 26, 2018: Kaleido Biosciences Announces New Leadership Team 20
Jan 03, 2018: Kaleido Biosciences Announces Appointment of Wendy Arnold as Senior Vice President, Human Resources 21
Dec 12, 2017: Kaleido Biosciences Expands Leadership Team with Appointment of Alison Lawton as President and Chief Operating Officer 22
Sep 18, 2017: Kaleido Biosciences Announces Appointment of Mike Bonney as CEO and Completion of Additional Fundraising 23
Other Significant Developments 24
Sep 18, 2017: Flagship Pioneering Unveils Kaleido Biosciences and First Chemistry Platform for Microbiome Health 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts 2
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kaleido Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kaleido Biosciences Raises USD101 Million in Series C Venture Financing 10
Kaleido Biosciences Raises Additional Funds through Venture Financing 12
Kaleido Biosciences Enters into Agreement with CoreBiome 13
Kaleido Biosciences Inc, Key Competitors 14
Kaleido Biosciences Inc, Key Employees 15

List of Figures
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kaleido Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Kaleido Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hilton Grand Vacations Inc (HGV):企業の財務・戦略的SWOT分析
    Hilton Grand Vacations Inc (HGV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Syngene International Ltd (SYNGENE):企業の財務・戦略的SWOT分析
    Summary Syngene International Ltd (Syngene), a subsidiary of Biocon Ltd, is a clinical research and contract research and manufacturing organization. The organization offers research, development and manufacturing programs. It also provides discovery medicinal chemistry, small molecule development, …
  • New Standard Energy Ltd (NSE):石油・ガス:M&Aディール及び事業提携情報
    Summary New Standard Energy Ltd (NSE), formerly Hawk Resources Ltd, is an oil and gas exploration and production company. The company carries out acquisition, exploration, and develops oil and gas; and hydrocarbon properties. It holds interest in production and development project in the Eagle Ford …
  • True Corporation Public Company Limited:戦略・SWOT・企業財務分析
    True Corporation Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary True Corporation Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Castrol India Ltd (CASTROLIND):企業の財務・戦略的SWOT分析
    Summary Castrol India Ltd (Castrol India), a subsidiary of Castrol Limited, is an oil and gas company that manufactures, distributes and markets lubricant products. The company provides products such as lubricants, premium lubricating oils and greases, antifreeze and coolant, greases, engine oils, d …
  • hVIVO Plc (HVO):製薬・医療:M&Aディール及び事業提携情報
    Summary hVIVO Plc (hVIVO), formerly Retroscreen Virology Ltd is a biopharma company that develops human-based analytical platform to accelerate drug discovery and development. The company enables organisations to discover drugs and diagnostics and accelerate new product development. It uses human di …
  • Horiba Ltd (6856):企業の財務・戦略的SWOT分析
    Summary Horiba Ltd (Horiba) is a manufacturer of precision instruments and systems. The company's product portfolio includes automotive mechatronics, emission measurement systems, test systems, in vitro diagnostic systems, gas and oxygen analyzers, monitoring devices, industrial conductivity meters, …
  • Jiangsu Jiuding New Material Co Ltd (002201):企業の財務・戦略的SWOT分析
    Jiangsu Jiuding New Material Co Ltd (002201) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Dongbu Corporation:企業の戦略・SWOT・財務情報
    Dongbu Corporation - Strategy, SWOT and Corporate Finance Report Summary Dongbu Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • South Broward Hospital District:企業の戦略的SWOT分析
    South Broward Hospital District - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Hitachi Ltd (6501)-エネルギー分野:企業M&A・提携分析
    Summary Hitachi, Ltd. (Hitachi) is a multinational company with operations in sectors such as engineering and electronics, nuclear, transportation and industrial systems. It manufactures and sells information and telecommunication systems, power systems, social infrastructure and industrial systems, …
  • BioSyent Inc (RX):企業の財務・戦略的SWOT分析
    Summary BioSyent Inc (BioSyent), formerly Hedley Technologies Inc is a specialty pharmaceutical company that offers in-licensing or acquiring innovative pharmaceutical products and technologies to enhance human health. The company’s products include Aguettant System for pre-filled syringes, FeraMAX …
  • Itochu Chemical Frontier Corp-製薬・医療分野:企業M&A・提携分析
    Summary Itochu Chemical Frontier Corp (ICF), formerly Ando Kaseihin KK, a subsidiary of Itochu Corporation, is a chemical company that manufactures and markets chemical products. The company operates in intermediate chemical division, silicone and adhesive division, osaka and nagoya division, perfor …
  • SI2 Technologies, Inc.:企業の戦略・SWOT・財務情報
    SI2 Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary SI2 Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Hycrete Inc:企業の戦略的SWOT分析
    Hycrete Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • The Mediterranean & Gulf Cooperative Insurance & Reinsurance Company (S.J.S.C):企業の戦略・SWOT・財務情報
    The Mediterranean & Gulf Cooperative Insurance & Reinsurance Company (S.J.S.C) - Strategy, SWOT and Corporate Finance Report Summary The Mediterranean & Gulf Cooperative Insurance & Reinsurance Company (S.J.S.C) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data …
  • Hunter Oil Corp (HOC):石油・ガス:M&Aディール及び事業提携情報
    Summary Hunter Oil Corp (HOC), formerly Enhanced Oil Resources Inc is an oil and gas company that offers energy production programs. The company offers production and rehabilitation of its legacy oil fields through full cycle development. It also provides full cycle development services such as rese …
  • Integra Holdings Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Integra Holdings Ltd (Integra Holdings), a subsidiary of Yissum Research Development Company of the Hebrew University of Jerusalem Ltd, is a healthcare investment company that invests in biopharmaceutical companies with products in clinical and pre-clinical stages of development. The company …
  • Valneva SE (VLA):企業の財務・戦略的SWOT分析
    Valneva SE (VLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Amsted Industries Inc:企業の戦略・SWOT・財務情報
    Amsted Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Amsted Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆